Bevacizumab can reduce VEGF levels and block neovascularization, temporarily normalize tumor tortuous blood vessels, improve tumor oxygenation and reduce interstitial fluid pressure, and restore drug delivery to the tumor. This evidence concerns the gene VEGFA and neoplasm.